Video
Dr. Taplin on ARMOR 3-SV Trial for Patients with mCRPC
Author(s):
Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).
Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).
Galeterone is an agent in development for this patient population, Taplin explains. It has a unique mechanism of action in that in addition to being an androgen receptor antagonist and a CYP17 lyase inhibitor, it also degrades the androgen receptor.
For this trial, patients will be screened for the presence of a blood-biomarker AR-V7. Patients who are AR-V7—positive and enrolled on the study will be randomized to receive galeterone or enzalutamide (Xtandi), with a primary endpoint of radiographic progression-free survival.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
